Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.45 |
| ▸ | LPL | P06858 | 5/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31752048 | 1.00 | FFAR1 (0.48) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL2680689 | 1.00 | FFAR1 (0.48) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL17548446 | 0.85 | P4HB (0.50) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL31195077 | 0.85 | LIPG (0.42) | LIPGLPLP4HBF11F2 | |
| SCHEMBL2032258 | 0.85 | ATM (0.42) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL16283845 | 0.85 | ATM (0.42) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL22264948 | 0.83 | FFAR1 (0.41) | FFAR1LIPGLPLP4HBALDH1A1 | |
| SCHEMBL22264949 | 0.83 | FFAR1 (0.41) | FFAR1LIPGLPLP4HBALDH1A1 | |
| SCHEMBL6510 | 0.81 | LIPG (0.40) | LIPGLPLP4HBF11CA1 | |
| SCHEMBL10517 | 0.81 | LIPG (0.40) | LIPGLPLP4HBF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | disclosed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | FFAR1 699/4885LIPG 77/4885LPL 68/4885 |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | PPP3CA, PTPA, PPP3CB | FFAR1 4715/4885LIPG 4508/4885LPL 1885/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | FFAR1 962/4885LIPG 1362/4885LPL 1548/4885 |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | FFAR1 1062/4885LIPG 1231/4885LPL 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.